cytosine has been researched along with Neoplasms in 170 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Excerpt | Relevance | Reference |
---|---|---|
" We have recently shown in in vitro studies that inflammation-mediated halogenated cytosine damage products can mimic 5-methylcytosine in directing enzymatic DNA methylation and in enhancing the binding of methyl-binding proteins whereas certain oxidative damage products inhibit both." | 8.84 | Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. ( Sowers, LC; Valinluck, V, 2007) |
"During chronic inflammation, neutrophil-secreted hypochlorous acid can damage nearby cells inducing the genomic accumulation of 5-chlorocytosine (5ClC), a known inflammation biomarker." | 7.81 | Intrinsic mutagenic properties of 5-chlorocytosine: A mechanistic connection between chronic inflammation and cancer. ( Chang, SC; Delaney, JC; Essigmann, JM; Fedeles, BI; Freudenthal, BD; Li, D; Singh, V; Wilson, SH; Yau, E, 2015) |
"The objective of this study was to develop a mechanism-based population pharmacokinetic/pharmacodynamic (PK/PD) model in describing troxacitabine-induced neutropenia in patients with cancer." | 7.77 | Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. ( Beeram, M; Lin, CC; Ng, CM; Patnaik, A; Takimoto, CH, 2011) |
" We have recently shown in in vitro studies that inflammation-mediated halogenated cytosine damage products can mimic 5-methylcytosine in directing enzymatic DNA methylation and in enhancing the binding of methyl-binding proteins whereas certain oxidative damage products inhibit both." | 4.84 | Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. ( Sowers, LC; Valinluck, V, 2007) |
" We have previously reported that the wild-type cytosine/cytosine genotype of a common Desmin synonymous single nucleotide polymorphism (C > T) (rs1058261) associated with cardiovascular diseases in a cohort of subjects from the Tampere adult population cardiovascular risk study." | 4.12 | The gene variant for desmin rs1058261 may protect against combined cancer and cardiovascular death, the Tampere adult population cardiovascular risk study. ( Kunnas, T; Nikkari, ST; Piesanen, J, 2022) |
"During chronic inflammation, neutrophil-secreted hypochlorous acid can damage nearby cells inducing the genomic accumulation of 5-chlorocytosine (5ClC), a known inflammation biomarker." | 3.81 | Intrinsic mutagenic properties of 5-chlorocytosine: A mechanistic connection between chronic inflammation and cancer. ( Chang, SC; Delaney, JC; Essigmann, JM; Fedeles, BI; Freudenthal, BD; Li, D; Singh, V; Wilson, SH; Yau, E, 2015) |
"The objective of this study was to develop a mechanism-based population pharmacokinetic/pharmacodynamic (PK/PD) model in describing troxacitabine-induced neutropenia in patients with cancer." | 3.77 | Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. ( Beeram, M; Lin, CC; Ng, CM; Patnaik, A; Takimoto, CH, 2011) |
"To assess the feasibility of administering troxacitabine, an L-nucleoside analog that is not a substrate for deoxycytidine deaminase, in combination with cisplatin, to identify pharmacokinetic interactions, and to seek preliminary evidence of antitumor activity." | 2.74 | Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. ( Beeram, M; De Bono, JS; Denis, LJ; Geyer, CE; Hao, D; Jolivet, J; Lin, CC; Ng, CM; Patnaik, A; Rha, SY; Rowinsky, EK; Takimoto, CH; Tolcher, AW, 2009) |
"Patients with solid tumors received troxacitabine as a progressively longer infusion on days 1-4 of a 28-day cycle." | 2.73 | Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. ( Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Lee, CK; Ma, WW; Messersmith, WA, 2008) |
"9 h after drug administration and the terminal elimination half-life was 1." | 2.72 | A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors. ( Braich, TA; Burch, PA; Camoriano, JK; Delaunoit, T; Erlichman, C; Kaur, JS; Kobayash, T; Reid, JM; Rubin, J, 2006) |
"Plasma samples from 111 cancer patients receiving troxacitabine (0." | 2.72 | Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. ( Baker, SD; Capparelli, E; Giles, F; Hidalgo, M; Jolivet, J; Lee, CK; Li, J; Moore, MJ; Rowinsky, EK, 2006) |
" After treatment on the fifth day, terminal half-life values averaged 39 (63) hours, and Cl(s) was reduced by approximately 20%, averaging 127 (27) mL/min." | 2.70 | Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. ( Baker, SD; de Bono, JS; Goetz, A; Hammond, LA; Hidalgo, M; Jolivet, J; Patnaik, A; Rowinsky, EK; Simmons, C; Siu, L; Stephenson, J; Weiss, G, 2002) |
"25 to 3g) and multiple-dose study with one-day dosing (1 or 2g, every one or two hours, three times a day), bropirimine treatment was well tolerated by the patients with cancer." | 2.68 | [Bropirimine (U-54461S) phase I clinical studies]. ( Furue, H, 1996) |
"Cytosine methylation plays a major role in the regulation of sequential and tissue-specific expression of genes." | 2.58 | Morphology-oriented epigenetic research. ( Haraguchi, R; Kitazawa, R; Kitazawa, S, 2018) |
"Both normal and cancerous cells, treated with drugs that block cytosine methylation of DNA, are preferentially killed by these drugs when they have p53 mutations and survive if they have a wild type protein." | 2.55 | The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA. ( Levine, AJ, 2017) |
"Given variability related to ethnicity, cancer types and detection methods, additional well-designed studies with larger sample sizes are required to further confirm our findings." | 2.55 | Decreased 5-hydroxymethylcytosine levels correlate with cancer progression and poor survival: a systematic review and meta-analysis. ( Chen, Z; Guo, L; He, J; Li, Y; Luo, M; Shi, X, 2017) |
"Causal treatment can be given for influenza, using a neuraminidase inhibitor, and respiratory syncytial virus, using ribavirin in addition to intravenous immunoglobulins." | 2.53 | Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. ( Berger, A; Christopeit, M; Hauf, E; Hentrich, M; Heussel, CP; Kalkreuth, J; Klein, M; Kochanek, M; Lehners, N; Mayer, K; Penack, O; Rieger, C; Schalk, E; Silling, G; Vehreschild, M; von Lilienfeld-Toal, M; Weber, T; Wolf, HH, 2016) |
"The role of miRNAs in cancer through hypo- and hypermethylation has also been explored and discussed." | 2.52 | Hydroxymethylation and its potential implication in DNA repair system: A review and future perspectives. ( Sehgal, M; Shukla, A; Singh, TR, 2015) |
"Understanding mechanisms driving cancer diversity is a critical step toward developing strategies to attenuate tumor evolution and adaptation." | 2.52 | APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. ( Harris, RS; McGranahan, N; Starrett, GJ; Swanton, C, 2015) |
"Sapacitabine is an orally bioavailable nucleoside analog prodrug that is in clinical trials for hematologic malignancies and solid tumors." | 2.48 | Sapacitabine for cancer. ( Kantarjian, H; Liu, X; Plunkett, W, 2012) |
"The use of anti-HIV drugs as cancer treatments is not new." | 2.45 | Anti-HIV drugs for cancer therapeutics: back to the future? ( Chow, WA; Guan, M; Jiang, C, 2009) |
"Cytosine methylation is a common form of post-replicative DNA modification seen in both bacteria and eukaryotes." | 2.43 | Cytosine methylation and DNA repair. ( Walsh, CP; Xu, GL, 2006) |
"The unique properties of a cancer cell are acquired through a stepwise accumulation of heritable changes in the information content of proto-oncogenes and tumor suppressor genes." | 2.41 | DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. ( Guldberg, P; Worm, J, 2002) |
"(1986) Cancer Res." | 2.40 | Mutagenic and epigenetic effects of DNA methylation. ( Gonzalgo, ML; Jones, PA, 1997) |
"The focus on genetic alterations in cancer research has perhaps led to an underestimation of the contribution by epigenetics." | 2.40 | Oncogenic mechanisms mediated by DNA methylation. ( Laird, PW, 1997) |
"Cytosine methylation is an important mechanism of gene regulation in mammals." | 2.39 | Experimental manipulation of genomic methylation. ( Jackson-Grusby, L; Jaenisch, R, 1996) |
"The causes of much of human cancer remain obscure." | 2.39 | Mechanisms of spontaneous human cancers. ( Venitt, S, 1996) |
"Mutations in lung cancer are therefore caused by a different mechanism than colorectal cancer and this presumably requires the direct interaction of carcinogens with DNA." | 2.38 | 5-Methylcytosine as an endogenous mutagen in the p53 tumor suppressor gene. ( Coetzee, GA; Jones, PA; Olumi, AF; Rideout, WM; Spruck, CH, 1991) |
"Additionally, DNMT2/TRDMT1 cancer mutant activity was collectively mediated by five enzymatic characteristics, which might impact gene expressions." | 1.91 | Determinants of DNMT2/TRDMT1 preference for substrates tRNA and DNA during the evolution. ( Cai, C; Chen, J; Chen, Y; Cheng, H; Li, H; Ma, Y; Qin, M; Xu, D; Xue, P; Yang, Y; Zhu, D, 2023) |
"Based on the B16 cancer model, a cocktail regimen was developed that combined BPSi-based PTT with doxorubicin (DOX) and cytosine-phosphate-guanosine (CpG)." | 1.72 | Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy. ( Cerullo, V; Fan, L; Feola, S; Lehto, VP; Pang, C; Qian, J; Song, C; Xu, W; Yu, H, 2022) |
" NV not only showed good tumor preventive effect, but also could successfully inhibited tumor development and metastasis when combined with anti-PD-L1, and induced long-term immune memory effect." | 1.72 | A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy. ( Chen, J; Chen, X; Feng, Y; Hao, K; Li, H; Li, Z; Lin, L; Meng, M; Tang, Z; Tian, H; Xu, C; Zhang, S, 2022) |
" Because activated natural killer T (NKT) cells can cooperate with pattern-recognition via TLRs to improve adaptive immune responses, we assessed the impact of combining a repeated dosing regimen of intratumoural CpG with a single intratumoural dose of the NKT cell agonist α-galactosylceramide (α-GalCer)." | 1.72 | Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect. ( Anderson, RJ; Burn, OK; Chen, CJ; Compton, BJ; Dasyam, N; Dundar, PR; Ferrer-Font, L; Godfrey, DI; Hermans, IF; Mattarollo, SR; Mayer, JU; Painter, GF; Prasit, KK; Ritchie, DS; Schmidt, AJ, 2022) |
"The mutations found in murine tumors are similar to those found in human skin cancers, and PMA promotes proliferation of human skin cells." | 1.51 | A Tumor-Promoting Phorbol Ester Causes a Large Increase in APOBEC3A Expression and a Moderate Increase in APOBEC3B Expression in a Normal Human Keratinocyte Cell Line without Increasing Genomic Uracils. ( Bhagwat, AS; Perera, MLW; Senevirathne, V; Siriwardena, SU; Stewart, J, 2019) |
"Alternatively, the cancer cell line HCT116 preserves global epigenetic heterogeneity independently of cell-cycle arrest." | 1.48 | Global delay in nascent strand DNA methylation. ( Akopian, V; Charlton, J; Clement, K; Downing, TL; Gnirke, A; Gu, H; Kiskinis, E; Klages, S; Meissner, A; Pop, R; Santos, DP; Smith, ZD; Timmermann, B; Tsankov, AM; Ziller, MJ, 2018) |
"Specifically, we discovered that lung cancer leads to a progressive global loss of 5hmC in cfDNA, whereas hepatocellular carcinoma and pancreatic cancer lead to disease-specific changes in the cell-free hydroxymethylome." | 1.46 | 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. ( Chen, Y; Chua, MS; Diao, J; Dong, B; Hu, J; Jeffrey, SS; Li, W; Liu, B; Ma, L; Quake, SR; So, S; Song, CX; Tian, Z; Wei, Y; Wheeler, A; Xie, D; Xiong, J; Yin, S; Zhang, W; Zhang, Y; Zhou, Z, 2017) |
"We reviewed data of 4 cancer patients with resistant CMV or herpes simplex virus (HSV) infections and were treated with brincidofovir under emergency IND application." | 1.43 | Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. ( Ariza-Heredia, EJ; Chemaly, RF; El Chaer, F; El-Haddad, D; Gulbis, AM; Mulanovich, VE; Shah, DP; Shpall, EJ; Vanichanan, J, 2016) |
"By analyzing genomic and exomic cancer databases, we show that >33% of dispersed APOBEC-induced mutations occur on the lagging strand during DNA replication, thus unraveling the major source of ssDNA targeted by APOBEC in cancer." | 1.43 | APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. ( Antonarakis, SE; Bazykin, GA; Nikolaev, SI; Popadin, KY; Seplyarskiy, VB; Soldatov, RA, 2016) |
"Notably, by screening cancer cell lines for growth defects after exposure to 5hmdC, we unexpectedly identify a subset of cell lines in which 5hmdC or 5fdC administration leads to cell lethality." | 1.42 | CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. ( Berridge, G; Goldin, R; Kessler, BM; Kriaucionis, S; Pugh, KM; Thézénas, ML; Zauri, M, 2015) |
"This cleansing function is required for cancer cell survival and to modulate Escherichia coli antibiotic sensitivity in a DNA polymerase (pol)-dependent manner." | 1.42 | Uncovering the polymerase-induced cytotoxicity of an oxidized nucleotide. ( Beard, WA; Freudenthal, BD; Kim, T; Perera, L; Schlick, T; Shock, DD; Wilson, SH, 2015) |
"Gemcitabine is a nucleoside analog with many faces, which shows a remarkable activity in a variety of cancers, most likely because it has a unique metabolism, a so-called self-potentiation." | 1.38 | Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine. ( Diaz, I; Muggia, F; Peters, GJ, 2012) |
"In squamous cell lung cancers, levels of 5hmdC were depleted substantially with up to 5-fold reduction compared with normal lung tissue." | 1.37 | 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. ( Jiang, Y; Jin, SG; Krex, D; Lu, Q; Pfeifer, GP; Qiu, R; Rauch, TA; Schackert, G; Wang, Y, 2011) |
"One possible mechanism of the cancer caused by CpG methylation is the gene repression, which is a binding-inhibition of the sequence-specific transcription factors bound to specific DNA-binding sites." | 1.37 | Effect of CpG methylation on DNA binding protein: molecular dynamics simulations of the homeodomain PITX2 bound to the methylated DNA. ( Sun, CK; Wang, HB; Yang, SY; Yang, XL; Yao, LF, 2011) |
"Epigenetic anti-cancer drugs with demethylating effects have shown to alter genome organization in mammalian cell nuclei." | 1.36 | Measuring topology of low-intensity DNA methylation sites for high-throughput assessment of epigenetic drug-induced effects in cancer cells. ( Farkas, DL; Gertych, A; Tajbakhsh, J, 2010) |
"With regard to cancer treatment, replication competent oncolytic adenoviruses have been safe in humans, although their efficacy has been variable." | 1.36 | Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. ( Bauerschmitz, GJ; Cerullo, V; Diaconu, I; Escutenaire, S; Hemminki, A; Hernandez-Alcoceba, R; Kanerva, A; Pesonen, S, 2010) |
"With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level." | 1.33 | Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005) |
"Human cancer cell lines are commonly used in basic cancer research to understand the behavior of primary tumors." | 1.32 | A systematic profile of DNA methylation in human cancer cell lines. ( Avila, S; Esteller, M; Fraga, MF; Guo, M; Herman, JG; Paz, MF; Pollan, M, 2003) |
"Relative risks (RRs) of cancer and 95% confidence intervals (CIs) were calculated by Cox proportional hazards regression analysis." | 1.32 | Integrin beta3 Leu33Pro homozygosity and risk of cancer. ( Bojesen, SE; Nordestgaard, BG; Tybjaerg-Hansen, A, 2003) |
"Second, tumors occurring in homozygous carriers of the methionine synthase 2756G allele show a lower number of hypermethylated CpG islands of tumor suppressor genes (P = 0." | 1.31 | Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. ( Avila, S; Capella, G; Esteller, M; Fraga, MF; Herman, JG; Paz, MF; Peinado, MA; Pollan, M; Sanchez-Cespedes, M, 2002) |
"The major mutational hot spots in human cancers occur at CpG sequences in the p53 gene." | 1.30 | Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. ( Chen, JX; Tang, MS; West, M; Zheng, Y, 1998) |
"In many cancers, the most frequent class of mutations is C to T changes within CG dinucleotides of the tumor suppressor gene p53." | 1.29 | A cytosine methyltransferase converts 5-methylcytosine in DNA to thymine. ( Bhagwat, AS; Yebra, MJ, 1995) |
"Most of the metastatic neoplasms had significantly lower genomic m5C contents than did most of the benign neoplasms or normal tissues." | 1.27 | The 5-methylcytosine content of DNA from human tumors. ( Ehrlich, M; Gama-Sosa, MA; Gehrke, CW; Kuo, KC; Oxenhandler, R; Slagel, VA; Trewyn, RW, 1983) |
"The results show that while tumors of the same histological type had similar 5-methylcytosine values, discrepancies existed between values obtained for fresh tumors and their corresponding cell lines." | 1.27 | Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants. ( Bogenmann, E; Flatau, E; Jones, PA, 1983) |
" Pharmacologic studies demonstrated a significant decrease in the bioavailability of the drug as it was administered in this study." | 1.27 | Phase I study of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP), an oral interferon inducer, in cancer patients. ( Fitzpatrick, FA; Gutknecht, GD; Hersh, EM; Reele, SB; Rios, A; Stringfellow, DA, 1986) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 27 (15.88) | 18.7374 |
1990's | 27 (15.88) | 18.2507 |
2000's | 34 (20.00) | 29.6817 |
2010's | 70 (41.18) | 24.3611 |
2020's | 12 (7.06) | 2.80 |
Authors | Studies |
---|---|
Manayia, AH | 1 |
Ilhami, FB | 1 |
Lee, AW | 1 |
Cheng, CC | 1 |
Song, N | 1 |
Sim, JA | 1 |
Dong, Q | 1 |
Zheng, Y | 2 |
Hou, L | 1 |
Li, Z | 2 |
Hsu, CW | 1 |
Pan, H | 1 |
Mulder, H | 1 |
Easton, J | 1 |
Walker, E | 1 |
Neale, G | 1 |
Wilson, CL | 1 |
Ness, KK | 1 |
Krull, KR | 1 |
Srivastava, DK | 1 |
Yasui, Y | 1 |
Zhang, J | 1 |
Hudson, MM | 1 |
Robison, LL | 1 |
Huang, IC | 1 |
Wang, Z | 3 |
Besaratinia, A | 1 |
Caceres, A | 1 |
Tommasi, S | 1 |
Prasit, KK | 1 |
Ferrer-Font, L | 1 |
Burn, OK | 1 |
Anderson, RJ | 1 |
Compton, BJ | 1 |
Schmidt, AJ | 1 |
Mayer, JU | 1 |
Chen, CJ | 1 |
Dasyam, N | 1 |
Ritchie, DS | 1 |
Godfrey, DI | 1 |
Mattarollo, SR | 1 |
Dundar, PR | 1 |
Painter, GF | 1 |
Hermans, IF | 1 |
Yu, J | 1 |
Chai, X | 1 |
Pang, J | 1 |
Zhao, H | 1 |
Xie, T | 1 |
Xu, L | 1 |
Sheng, R | 1 |
Li, D | 2 |
Zeng, S | 1 |
Hou, T | 1 |
Kang, Y | 1 |
Xu, W | 1 |
Pang, C | 1 |
Song, C | 1 |
Qian, J | 1 |
Feola, S | 1 |
Cerullo, V | 2 |
Fan, L | 1 |
Yu, H | 1 |
Lehto, VP | 1 |
Zhang, S | 1 |
Feng, Y | 1 |
Meng, M | 1 |
Li, H | 2 |
Lin, L | 1 |
Xu, C | 1 |
Chen, J | 2 |
Hao, K | 1 |
Tang, Z | 1 |
Tian, H | 1 |
Chen, X | 1 |
Piesanen, J | 1 |
Kunnas, T | 1 |
Nikkari, ST | 1 |
An, J | 1 |
Ko, M | 1 |
Zhu, D | 1 |
Yang, Y | 1 |
Ma, Y | 1 |
Chen, Y | 3 |
Xue, P | 1 |
Qin, M | 1 |
Xu, D | 1 |
Cai, C | 1 |
Cheng, H | 1 |
Chen, H | 1 |
Yang, H | 2 |
Zhu, X | 1 |
Yadav, T | 1 |
Ouyang, J | 1 |
Truesdell, SS | 1 |
Tan, J | 1 |
Wang, Y | 2 |
Duan, M | 1 |
Wei, L | 1 |
Zou, L | 1 |
Levine, AS | 1 |
Vasudevan, S | 1 |
Lan, L | 1 |
Sanchez-Martin, V | 1 |
Lopez-Pujante, C | 1 |
Soriano-Rodriguez, M | 1 |
Garcia-Salcedo, JA | 1 |
Youn, HD | 1 |
López, V | 1 |
Fernández, AF | 1 |
Fraga, MF | 3 |
Coulter, JB | 1 |
Lopez-Bertoni, H | 1 |
Kuhns, KJ | 1 |
Lee, RS | 1 |
Laterra, J | 1 |
Bressler, JP | 1 |
Song, CX | 2 |
Yin, S | 1 |
Ma, L | 1 |
Wheeler, A | 1 |
Zhang, Y | 4 |
Liu, B | 1 |
Xiong, J | 1 |
Zhang, W | 1 |
Hu, J | 1 |
Zhou, Z | 1 |
Dong, B | 1 |
Tian, Z | 1 |
Jeffrey, SS | 1 |
Chua, MS | 1 |
So, S | 1 |
Li, W | 1 |
Wei, Y | 1 |
Diao, J | 1 |
Xie, D | 1 |
Quake, SR | 1 |
Liu, Z | 1 |
Dong, K | 2 |
Liu, C | 2 |
Ran, X | 1 |
Pu, F | 1 |
Ju, E | 1 |
Ren, J | 1 |
Qu, X | 1 |
Charlton, J | 1 |
Downing, TL | 1 |
Smith, ZD | 1 |
Gu, H | 1 |
Clement, K | 1 |
Pop, R | 1 |
Akopian, V | 1 |
Klages, S | 1 |
Santos, DP | 1 |
Tsankov, AM | 1 |
Timmermann, B | 1 |
Ziller, MJ | 1 |
Kiskinis, E | 1 |
Gnirke, A | 1 |
Meissner, A | 1 |
Kitazawa, S | 1 |
Haraguchi, R | 1 |
Kitazawa, R | 1 |
Siriwardena, SU | 1 |
Perera, MLW | 1 |
Senevirathne, V | 1 |
Stewart, J | 1 |
Bhagwat, AS | 2 |
Bunkar, N | 1 |
Shandilya, R | 1 |
Bhargava, A | 1 |
Samarth, RM | 1 |
Tiwari, R | 1 |
Mishra, DK | 1 |
Srivastava, RK | 1 |
Sharma, RS | 1 |
Lohiya, NK | 1 |
Mishra, PK | 1 |
Matsumoto, T | 1 |
Shirakawa, K | 1 |
Yokoyama, M | 1 |
Fukuda, H | 1 |
Sarca, AD | 1 |
Koyabu, S | 1 |
Yamazaki, H | 1 |
Kazuma, Y | 1 |
Matsui, H | 1 |
Maruyama, W | 1 |
Nagata, K | 1 |
Tanabe, F | 1 |
Kobayashi, M | 1 |
Shindo, K | 1 |
Morishita, R | 1 |
Sato, H | 1 |
Takaori-Kondo, A | 1 |
Haffner, MC | 1 |
Pellakuru, LG | 1 |
Ghosh, S | 1 |
Lotan, TL | 1 |
Nelson, WG | 1 |
De Marzo, AM | 1 |
Yegnasubramanian, S | 1 |
Głowacki, S | 1 |
Błasiak, J | 1 |
Cadet, J | 1 |
Wagner, JR | 1 |
Kohli, RM | 1 |
Ye, C | 1 |
Li, L | 1 |
Laird, A | 1 |
Thomson, JP | 1 |
Harrison, DJ | 1 |
Meehan, RR | 1 |
Johansson, C | 1 |
Tumber, A | 1 |
Che, K | 1 |
Cain, P | 1 |
Nowak, R | 1 |
Gileadi, C | 1 |
Oppermann, U | 1 |
Wu, YC | 1 |
Ling, ZQ | 2 |
Pfeifer, GP | 4 |
Xiong, W | 1 |
Hahn, MA | 1 |
Jin, SG | 2 |
Delatte, B | 1 |
Deplus, R | 1 |
Fuks, F | 1 |
Shen, L | 1 |
He, C | 1 |
Boele, J | 1 |
Persson, H | 1 |
Shin, JW | 1 |
Ishizu, Y | 1 |
Newie, IS | 1 |
Søkilde, R | 1 |
Hawkins, SM | 1 |
Coarfa, C | 1 |
Ikeda, K | 1 |
Takayama, K | 1 |
Horie-Inoue, K | 1 |
Ando, Y | 1 |
Burroughs, AM | 1 |
Sasaki, C | 1 |
Suzuki, C | 1 |
Sakai, M | 1 |
Aoki, S | 1 |
Ogawa, A | 1 |
Hasegawa, A | 1 |
Lizio, M | 1 |
Kaida, K | 1 |
Teusink, B | 1 |
Carninci, P | 1 |
Suzuki, H | 1 |
Inoue, S | 1 |
Gunaratne, PH | 1 |
Rovira, C | 1 |
Hayashizaki, Y | 1 |
de Hoon, MJ | 1 |
Arab, K | 1 |
Park, YJ | 1 |
Lindroth, AM | 1 |
Schäfer, A | 1 |
Oakes, C | 1 |
Weichenhan, D | 1 |
Lukanova, A | 1 |
Lundin, E | 1 |
Risch, A | 1 |
Meister, M | 1 |
Dienemann, H | 1 |
Dyckhoff, G | 1 |
Herold-Mende, C | 1 |
Grummt, I | 1 |
Niehrs, C | 1 |
Plass, C | 2 |
Huang, Y | 1 |
Rao, A | 1 |
Lian, CG | 1 |
Xu, S | 1 |
Guo, W | 1 |
Yan, J | 1 |
Frank, MY | 1 |
Liu, R | 1 |
Murphy, GF | 1 |
Chen, T | 1 |
Ficz, G | 1 |
Gribben, JG | 1 |
Freudenthal, BD | 2 |
Beard, WA | 1 |
Perera, L | 1 |
Shock, DD | 1 |
Kim, T | 1 |
Schlick, T | 1 |
Wilson, SH | 2 |
Rodger, EJ | 1 |
Chatterjee, A | 1 |
Morison, IM | 1 |
Chowdhury, B | 1 |
Cho, IH | 1 |
Hahn, N | 1 |
Irudayaraj, J | 1 |
Andrei, G | 1 |
Topalis, D | 1 |
De Schutter, T | 1 |
Snoeck, R | 1 |
Kroeze, LI | 1 |
van der Reijden, BA | 1 |
Jansen, JH | 1 |
Shukla, A | 1 |
Sehgal, M | 1 |
Singh, TR | 1 |
Vasanthakumar, A | 1 |
Godley, LA | 1 |
Tu, J | 1 |
Liao, J | 1 |
Luk, AC | 1 |
Tang, NL | 1 |
Chan, WY | 1 |
Lee, TL | 1 |
Swanton, C | 1 |
McGranahan, N | 1 |
Starrett, GJ | 1 |
Harris, RS | 1 |
Zauri, M | 1 |
Berridge, G | 1 |
Thézénas, ML | 1 |
Pugh, KM | 1 |
Goldin, R | 1 |
Kessler, BM | 1 |
Kriaucionis, S | 1 |
Sivanand, S | 1 |
Wellen, KE | 1 |
Fedeles, BI | 1 |
Yau, E | 1 |
Singh, V | 1 |
Chang, SC | 1 |
Delaney, JC | 1 |
Essigmann, JM | 1 |
Neupane, M | 1 |
Clark, AP | 1 |
Landini, S | 1 |
Birkbak, NJ | 1 |
Eklund, AC | 1 |
Lim, E | 1 |
Culhane, AC | 1 |
Barry, WT | 1 |
Schumacher, SE | 1 |
Beroukhim, R | 1 |
Szallasi, Z | 1 |
Vidal, M | 1 |
Hill, DE | 1 |
Silver, DP | 1 |
Popis, MC | 1 |
Blanco, S | 1 |
Frye, M | 1 |
Seplyarskiy, VB | 1 |
Soldatov, RA | 1 |
Popadin, KY | 1 |
Antonarakis, SE | 1 |
Bazykin, GA | 1 |
Nikolaev, SI | 1 |
Liu, FT | 1 |
Zhu, PQ | 1 |
Ou, YX | 1 |
Liu, WW | 1 |
Xia, GF | 1 |
Luo, HL | 1 |
Pataillot-Meakin, T | 1 |
Pillay, N | 1 |
Beck, S | 2 |
Rasmussen, KD | 1 |
Helin, K | 1 |
El-Haddad, D | 1 |
El Chaer, F | 1 |
Vanichanan, J | 1 |
Shah, DP | 1 |
Ariza-Heredia, EJ | 1 |
Mulanovich, VE | 1 |
Gulbis, AM | 1 |
Shpall, EJ | 1 |
Chemaly, RF | 1 |
von Lilienfeld-Toal, M | 1 |
Berger, A | 1 |
Christopeit, M | 1 |
Hentrich, M | 1 |
Heussel, CP | 1 |
Kalkreuth, J | 1 |
Klein, M | 1 |
Kochanek, M | 1 |
Penack, O | 1 |
Hauf, E | 1 |
Rieger, C | 1 |
Silling, G | 1 |
Vehreschild, M | 1 |
Weber, T | 1 |
Wolf, HH | 1 |
Lehners, N | 1 |
Schalk, E | 1 |
Mayer, K | 1 |
Chen, Z | 1 |
Shi, X | 1 |
Guo, L | 1 |
Li, Y | 1 |
Luo, M | 1 |
He, J | 1 |
Levine, AJ | 1 |
Chow, WA | 1 |
Jiang, C | 1 |
Guan, M | 1 |
Lao, VV | 1 |
Herring, JL | 1 |
Kim, CH | 1 |
Darwanto, A | 1 |
Soto, U | 1 |
Sowers, LC | 2 |
Lin, CC | 2 |
Beeram, M | 2 |
Rowinsky, EK | 3 |
Takimoto, CH | 2 |
Ng, CM | 2 |
Geyer, CE | 1 |
Denis, LJ | 1 |
De Bono, JS | 2 |
Hao, D | 1 |
Tolcher, AW | 1 |
Rha, SY | 1 |
Jolivet, J | 6 |
Patnaik, A | 3 |
Suter, JD | 1 |
Howard, DJ | 1 |
Shi, H | 1 |
Caldwell, CW | 1 |
Fan, X | 1 |
Diaconu, I | 1 |
Escutenaire, S | 1 |
Kanerva, A | 1 |
Bauerschmitz, GJ | 1 |
Hernandez-Alcoceba, R | 1 |
Pesonen, S | 1 |
Hemminki, A | 1 |
Olinski, R | 2 |
Jurgowiak, M | 2 |
Zaremba, T | 1 |
Gertych, A | 1 |
Farkas, DL | 1 |
Tajbakhsh, J | 1 |
Riahi, S | 1 |
Eynollahi, S | 1 |
Ganjali, MR | 1 |
Green, SR | 2 |
Choudhary, AK | 1 |
Fleming, IN | 1 |
Su, Z | 1 |
Han, L | 1 |
Zhao, Z | 1 |
Boeva, V | 1 |
Zinovyev, A | 1 |
Bleakley, K | 1 |
Vert, JP | 1 |
Janoueix-Lerosey, I | 1 |
Delattre, O | 1 |
Barillot, E | 1 |
Lingaraju, GM | 1 |
Davis, CA | 1 |
Setser, JW | 1 |
Samson, LD | 1 |
Drennan, CL | 1 |
Mikulski, D | 1 |
Szeląg, M | 1 |
Molski, M | 1 |
Yang, SY | 1 |
Yang, XL | 1 |
Yao, LF | 1 |
Wang, HB | 1 |
Sun, CK | 1 |
Münzel, M | 1 |
Globisch, D | 1 |
Carell, T | 1 |
Tjon Pian Gi, RE | 1 |
Dietz, A | 1 |
Djukic, V | 1 |
Eckel, HE | 1 |
Friedrich, G | 1 |
Golusinski, W | 1 |
Hantzakos, A | 1 |
Lawson, G | 1 |
Remacle, M | 1 |
Rihkanen, H | 1 |
Dikkers, FG | 1 |
Jiang, Y | 1 |
Qiu, R | 1 |
Rauch, TA | 1 |
Schackert, G | 1 |
Krex, D | 1 |
Lu, Q | 1 |
Kudo, Y | 1 |
Tateishi, K | 1 |
Yamamoto, K | 1 |
Yamamoto, S | 1 |
Asaoka, Y | 1 |
Ijichi, H | 1 |
Nagae, G | 1 |
Yoshida, H | 1 |
Aburatani, H | 1 |
Koike, K | 1 |
Liu, X | 1 |
Kantarjian, H | 1 |
Plunkett, W | 1 |
Liu, Y | 1 |
Bai, F | 1 |
Zhang, JY | 1 |
Ma, SH | 1 |
Liu, J | 1 |
Xu, ZD | 1 |
Zhu, HG | 1 |
Ye, D | 1 |
Guan, KL | 1 |
Xiong, Y | 1 |
Muggia, F | 1 |
Diaz, I | 1 |
Peters, GJ | 1 |
Tan, L | 1 |
Shi, YG | 1 |
Krečmerová, M | 1 |
Otmar, M | 1 |
Guz, J | 1 |
Kinney, SR | 1 |
Pradhan, S | 1 |
Paz, MF | 2 |
Avila, S | 2 |
Pollan, M | 2 |
Capella, G | 1 |
Peinado, MA | 1 |
Sanchez-Cespedes, M | 1 |
Herman, JG | 3 |
Esteller, M | 2 |
Piyathilake, CJ | 1 |
Johanning, GL | 1 |
Worm, J | 1 |
Guldberg, P | 1 |
Ecker, G | 1 |
Novik, KL | 1 |
Nimmrich, I | 1 |
Genc, B | 1 |
Maier, S | 1 |
Piepenbrock, C | 1 |
Olek, A | 1 |
Guo, M | 1 |
Bojesen, SE | 1 |
Tybjaerg-Hansen, A | 1 |
Nordestgaard, BG | 1 |
KAMMEN, HO | 1 |
HURLBERT, RB | 1 |
HAREL, J | 1 |
HAREL, L | 1 |
LACOUR, F | 1 |
BOER, A | 1 |
IMBENOTTE, J | 1 |
GREKH, IF | 2 |
TURBINA, IL | 2 |
KARLINSKAIA, RS | 2 |
AKSAMITNAIA, Ia | 1 |
EVANS, JS | 3 |
BOSTWICK, L | 2 |
MENGEL, GD | 3 |
MUSSER, EA | 1 |
RAPP, F | 1 |
MELNICK, JL | 1 |
KITAHARA, T | 1 |
RABOTTI, G | 1 |
MANOILOV, SE | 1 |
KITAVIN, GS | 1 |
COMAR, VE | 1 |
ORLOVA, EU | 1 |
CHU, MY | 1 |
FISCHER, GA | 1 |
OKAMURA, N | 1 |
BUSCH, H | 1 |
Matsuda, A | 1 |
Sasaki, T | 1 |
Gourdeau, H | 2 |
Leblond, L | 1 |
Hamelin, B | 1 |
Ouellet, F | 1 |
Boudreau, C | 1 |
Custeau, D | 1 |
Richard, A | 1 |
Gilbert, MJ | 1 |
Sandoval Guerrero, K | 1 |
Revilla Vázquez, A | 1 |
Segura-Pacheco, B | 1 |
Dueñas-Gonzalez, A | 1 |
Hoffman, RM | 2 |
Cieplik, J | 1 |
Inglis, AF | 1 |
Delaunoit, T | 1 |
Burch, PA | 1 |
Reid, JM | 1 |
Camoriano, JK | 1 |
Kobayash, T | 1 |
Braich, TA | 1 |
Kaur, JS | 1 |
Rubin, J | 1 |
Erlichman, C | 1 |
Walsh, CP | 2 |
Xu, GL | 1 |
Gekeler, V | 1 |
Gimmnich, P | 1 |
Hofmann, HP | 1 |
Grebe, C | 1 |
Römmele, M | 1 |
Leja, A | 1 |
Baudler, M | 1 |
Benimetskaya, L | 1 |
Gonser, B | 1 |
Pieles, U | 1 |
Maier, T | 1 |
Wagner, T | 1 |
Sanders, K | 1 |
Beck, JF | 1 |
Hanauer, G | 1 |
Stein, CA | 1 |
Asada, K | 1 |
Asada, R | 1 |
Yoshiji, H | 1 |
Fukui, H | 1 |
Floyd, RA | 1 |
Kotake, Y | 1 |
Lee, CK | 2 |
Li, J | 1 |
Giles, F | 1 |
Moore, MJ | 1 |
Hidalgo, M | 3 |
Capparelli, E | 1 |
Baker, SD | 4 |
Valinluck, V | 1 |
Serova, M | 1 |
Galmarini, CM | 1 |
Ghoul, A | 1 |
Benhadji, K | 1 |
Chiao, J | 1 |
Faivre, S | 1 |
Cvitkovic, E | 1 |
Le Tourneau, C | 1 |
Calvo, F | 1 |
Raymond, E | 1 |
Jimeno, A | 1 |
Messersmith, WA | 1 |
Ma, WW | 1 |
Laheru, D | 1 |
Donehower, RC | 1 |
Riggs, AD | 1 |
Jones, PA | 13 |
Gama-Sosa, MA | 1 |
Slagel, VA | 1 |
Trewyn, RW | 1 |
Oxenhandler, R | 1 |
Kuo, KC | 1 |
Gehrke, CW | 1 |
Ehrlich, M | 1 |
Nyce, J | 1 |
Weinhouse, S | 1 |
Magee, PN | 1 |
Diala, ES | 1 |
Cheah, MS | 1 |
Rowitch, D | 1 |
Flatau, E | 1 |
Bogenmann, E | 2 |
Wasternack, C | 1 |
Yebra, MJ | 1 |
Little, M | 1 |
Wainwright, B | 1 |
Merlo, A | 1 |
Mao, L | 1 |
Lee, DJ | 1 |
Gabrielson, E | 1 |
Burger, PC | 1 |
Baylin, SB | 1 |
Sidransky, D | 1 |
Holliday, R | 1 |
Grigg, GW | 1 |
Goodman, JI | 1 |
Counts, JL | 1 |
von Borstel, RC | 1 |
Hennig, UG | 1 |
Spruck, CH | 3 |
Rideout, WM | 3 |
Harris, CC | 1 |
Heby, O | 1 |
Venitt, S | 1 |
Bird, AP | 1 |
Furue, H | 1 |
Jackson-Grusby, L | 1 |
Jaenisch, R | 1 |
Gonzalgo, ML | 2 |
Wachsman, JT | 1 |
Zingg, JM | 1 |
Laird, PW | 1 |
Yoder, JA | 1 |
Bestor, TH | 2 |
Holmquist, GP | 1 |
Robertson, KD | 2 |
Denissenko, MF | 1 |
Chen, JX | 1 |
West, M | 1 |
Tang, MS | 1 |
Warnecke, PM | 1 |
Boos, G | 1 |
Stopper, H | 1 |
Santini, V | 1 |
Kantarjian, HM | 1 |
Issa, JP | 1 |
Costello, JF | 1 |
Watanabe, Y | 1 |
Fujiyama, A | 1 |
Ichiba, Y | 1 |
Hattori, M | 1 |
Yada, T | 1 |
Sakaki, Y | 1 |
Ikemura, T | 1 |
Stephenson, J | 1 |
Hammond, LA | 1 |
Weiss, G | 1 |
Goetz, A | 1 |
Siu, L | 2 |
Simmons, C | 1 |
Bélanger, K | 1 |
Moore, M | 1 |
Dionne, J | 1 |
Maclean, M | 1 |
Soulières, D | 1 |
Wainman, N | 1 |
Seymour, L | 1 |
Lakings, DB | 1 |
Waalkes, TP | 1 |
Mrochek, JE | 1 |
Sutow, WW | 1 |
Sullivan, MP | 1 |
Bingham, CA | 1 |
Shen, JC | 1 |
Tsai, YC | 1 |
Coetzee, GA | 1 |
Olumi, AF | 1 |
Rios, A | 1 |
Stringfellow, DA | 1 |
Fitzpatrick, FA | 1 |
Reele, SB | 1 |
Gutknecht, GD | 1 |
Hersh, EM | 1 |
Chandler, LA | 2 |
DeClerck, YA | 1 |
Mishra, PC | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer[NCT02363647] | 10 participants (Actual) | Interventional | 2015-01-31 | Terminated (stopped due to No Current Funding) | |||
Addition of Gemcitabine to the Standard Reduced Busulfan and Cyclophosphamide (BUCY2) Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia[NCT03339700] | Phase 2 | 15 participants (Anticipated) | Interventional | 2018-09-15 | Recruiting | ||
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial[NCT04482621] | Phase 2 | 33 participants (Actual) | Interventional | 2020-09-14 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
74 reviews available for cytosine and Neoplasms
Article | Year |
---|---|
DNA Hydroxymethylation in Smoking-Associated Cancers.
Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; Epigenesis, Genetic; Mammals; Neoplasms; Proto | 2022 |
Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation.
Topics: 5-Methylcytosine; Animals; Cell Differentiation; Cell Transformation, Neoplastic; Cytosine; Dioxygen | 2023 |
An Updated Focus on Quadruplex Structures as Potential Therapeutic Targets in Cancer.
Topics: Cytosine; DNA; G-Quadruplexes; Gene Expression Regulation, Neoplastic; Guanine; Humans; Molecular Ta | 2020 |
The role of 5-hydroxymethylcytosine in development, aging and age-related diseases.
Topics: 5-Methylcytosine; Aging; Animals; Cell Differentiation; Cytosine; DNA Methylation; Epigenesis, Genet | 2017 |
Morphology-oriented epigenetic research.
Topics: CpG Islands; Cytosine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Neoplasms; Prom | 2018 |
Nano-engineered flavonoids for cancer protection.
Topics: Acetylation; Animals; Cell Line, Tumor; Cytosine; Dietary Supplements; DNA Methylation; Drug Deliver | 2019 |
[Role of 5-hydroxymethylcytosine and TET proteins in epigenetic regulation of gene expression].
Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Hem | 2013 |
TET enzymatic oxidation of 5-methylcytosine, 5-hydroxymethylcytosine and 5-formylcytosine.
Topics: 5-Methylcytosine; Animals; Cytosine; Dioxygenases; DNA; DNA Methylation; DNA Repair; Humans; Models, | 2014 |
TET enzymes, TDG and the dynamics of DNA demethylation.
Topics: 5-Methylcytosine; Animals; Blastocyst; Cellular Reprogramming; Cytosine; DNA Methylation; DNA Repair | 2013 |
5-hydroxymethylcytosine: a new insight into epigenetics in cancer.
Topics: 5-Methylcytosine; Animals; Brain Neoplasms; Cytosine; Dioxygenases; DNA Methylation; DNA-Binding Pro | 2014 |
5-hydroxymethylcytosine profiling as an indicator of cellular state.
Topics: 5-Methylcytosine; Animals; Biomarkers, Tumor; Cytosine; DNA Methylation; Epigenesis, Genetic; Gene E | 2013 |
The roles of Jumonji-type oxygenases in human disease.
Topics: Cytosine; DNA Methylation; Epigenesis, Genetic; Humans; Inflammation; Jumonji Domain-Containing Hist | 2014 |
The role of TET family proteins and 5-hydroxymethylcytosine in human tumors.
Topics: 5-Methylcytosine; Cell Transformation, Neoplastic; Cytosine; DNA Methylation; DNA-Binding Proteins; | 2014 |
The role of 5-hydroxymethylcytosine in human cancer.
Topics: 5-Methylcytosine; Cytosine; DNA Methylation; DNA, Neoplasm; Humans; Neoplasms; Oxidation-Reduction | 2014 |
Playing TETris with DNA modifications.
Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Gen | 2014 |
Mechanism and function of oxidative reversal of DNA and RNA methylation.
Topics: 5-Methylcytosine; Animals; Cytosine; DNA; DNA Methylation; Escherichia coli; Gene Expression Regulat | 2014 |
Connections between TET proteins and aberrant DNA modification in cancer.
Topics: 5-Methylcytosine; Azacitidine; Cytosine; Decitabine; Dioxygenases; DNA Methylation; DNA Modification | 2014 |
Loss of 5-hydroxymethylcytosine in cancer: cause or consequence?
Topics: 5-Methylcytosine; Animals; Cytosine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; DNA, Neopl | 2014 |
5-hydroxymethylcytosine: a potential therapeutic target in cancer.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents; Cytosine; DNA (Cytosine-5-)-Methyltransferases; DN | 2014 |
Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Cell Proliferation; Cidofovir; C | 2015 |
5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer.
Topics: 5-Methylcytosine; Biomarkers, Tumor; Cytosine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; | 2015 |
Hydroxymethylation and its potential implication in DNA repair system: A review and future perspectives.
Topics: 5-Methylcytosine; Animals; Cytosine; DNA Repair; Humans; Mental Disorders; Neoplasms; Neurodegenerat | 2015 |
5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy.
Topics: 5-Methylcytosine; Cytosine; Dioxygenases; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA | 2015 |
MicroRNAs mediated targeting on the Yin-yang dynamics of DNA methylation in disease and development.
Topics: Animals; Chromatin Assembly and Disassembly; Cytosine; DNA (Cytosine-5-)-Methyltransferases; DNA Met | 2015 |
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
Topics: APOBEC Deaminases; Cytidine Deaminase; Cytosine; Cytosine Deaminase; Deamination; Evolution, Molecul | 2015 |
Posttranscriptional methylation of transfer and ribosomal RNA in stress response pathways, cell differentiation, and cancer.
Topics: Cell Differentiation; Cytidine; Cytosine; Humans; Methylation; Methyltransferases; Neoplasms; RNA Pr | 2016 |
Positive association between IL-16 rs1131445 polymorphism and cancer risk: a meta-analysis.
Topics: Alleles; Asian People; Biomarkers, Tumor; Cytosine; Databases, Factual; Evidence-Based Medicine; Gen | 2016 |
Role of TET enzymes in DNA methylation, development, and cancer.
Topics: Animals; Cytosine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Gene Ex | 2016 |
Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology.
Topics: Adenovirus Infections, Human; Antiviral Agents; Cidofovir; Community-Acquired Infections; Cytosine; | 2016 |
Decreased 5-hydroxymethylcytosine levels correlate with cancer progression and poor survival: a systematic review and meta-analysis.
Topics: 5-Methylcytosine; Cytosine; DNA Methylation; Humans; Lymphatic Metastasis; Neoplasms; Prognosis | 2017 |
The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Death; Cytosine; Decitabine; DNA Methyla | 2017 |
Anti-HIV drugs for cancer therapeutics: back to the future?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cidofovir; Cytosine; HIV Protease Inhibitors | 2009 |
Uracil in DNA--its biological significance.
Topics: Animals; B-Lymphocytes; Cytosine; Cytosine Deaminase; DNA; Drosophila melanogaster; Escherichia coli | 2010 |
5-Hydroxymethylcytosine, the sixth base of the genome.
Topics: 5-Methylcytosine; Animals; Bacteriophages; Cell Differentiation; Central Nervous System; Chromatogra | 2011 |
Sapacitabine for cancer.
Topics: Animals; Arabinonucleosides; Cell Cycle; Clinical Trials as Topic; Cytosine; DNA Damage; Drug Evalua | 2012 |
Tet family proteins and 5-hydroxymethylcytosine in development and disease.
Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; DNA-Binding Proteins; Embryonic Development; E | 2012 |
5-azacytosine compounds in medicinal chemistry: current stage and future perspectives.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Azacitidine; Cytosine; DNA Methylation; Drug Discov | 2012 |
[Oxidation and deamination of nucleobases as an epigenetic tool].
Topics: 5-Methylcytosine; Animals; Base Composition; Chromatin Assembly and Disassembly; Cytosine; Deaminati | 2012 |
Ten eleven translocation enzymes and 5-hydroxymethylation in mammalian development and cancer.
Topics: 5-Methylcytosine; Animals; Cell Differentiation; Cytosine; Dioxygenases; DNA Methylation; DNA-Bindin | 2013 |
DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Chromatin; CpG Islands; Cytosine; DNA Methylation; DNA Mod | 2002 |
Epigenomics: genome-wide study of methylation phenomena.
Topics: Autoimmune Diseases; Chromosome Mapping; CpG Islands; Cytosine; DNA Methylation; DNA Modification Me | 2002 |
Antitumor activity of sugar-modified cytosine nucleosides.
Topics: Animals; Antimetabolites, Antineoplastic; Carbohydrates; Cytosine; Humans; Neoplasms; Pyrimidine Nuc | 2004 |
[Troxacitabine].
Topics: Acute Disease; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, P | 2004 |
Pyrimidines as the cytostatic drugs.
Topics: Animals; Antineoplastic Agents; Cytosine; Drug Design; Folic Acid; Humans; Neoplasms; Pyrimidines | 1992 |
Cytosine methylation and DNA repair.
Topics: 5-Methylcytosine; Animals; Bacteria; CpG Islands; Cytosine; Dealkylation; Deamination; DNA Glycosyla | 2006 |
Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers.
Topics: Animals; Cell Transformation, Neoplastic; Cytosine; DNA Damage; DNA Methylation; Epigenesis, Genetic | 2007 |
5-methylcytosine, gene regulation, and cancer.
Topics: 5-Methylcytosine; Animals; Azacitidine; Base Sequence; Carcinogens; Cell Transformation, Neoplastic; | 1983 |
5-Methylcytosine depletion during tumour development: an extension of the miscoding concept.
Topics: 5-Methylcytosine; Alkylation; Amino Acid Metabolism, Inborn Errors; Animals; Carcinogens; Cell Trans | 1983 |
Degradation of pyrimidines and pyrimidine analogs--pathways and mutual influences.
Topics: Aminoisobutyric Acids; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Aza Compounds; Bar | 1980 |
DNA methylation and mutation.
Topics: 5-Methylcytosine; Animals; Base Composition; Cytosine; Dinucleoside Phosphates; DNA; DNA Repair; Hum | 1993 |
Spontaneous mutations and fidelogens.
Topics: 5-Methylcytosine; Animals; Antimutagenic Agents; Apurinic Acid; Cytosine; DNA Repair; DNA Replicatio | 1993 |
DNA methylation and cancer.
Topics: 5-Methylcytosine; Animals; Cytosine; Dinucleoside Phosphates; DNA; DNA Repair; Genes, p53; Genes, Tu | 1993 |
The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene.
Topics: 5-Methylcytosine; Cytosine; DNA, Neoplasm; Genes, p53; Humans; Mutation; Neoplasms; Tumor Suppressor | 1996 |
DNA methylation and polyamines in embryonic development and cancer.
Topics: 5-Methylcytosine; Animals; Cell Transformation, Neoplastic; Cytosine; DNA; DNA (Cytosine-5-)-Methylt | 1995 |
DNA methylation errors and cancer.
Topics: 5-Methylcytosine; Animals; Cytosine; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; | 1996 |
Mechanisms of spontaneous human cancers.
Topics: 5-Methylcytosine; CpG Islands; Cytosine; Disease Susceptibility; DNA Damage; Environmental Exposure; | 1996 |
The relationship of DNA methylation to cancer.
Topics: 5-Methylcytosine; Azacitidine; CpG Islands; Cytosine; Decitabine; DNA Methylation; Enzyme Inhibitors | 1996 |
Experimental manipulation of genomic methylation.
Topics: Animals; Cytosine; DNA; DNA Methylation; DNA, Neoplasm; Genome; Humans; Mice; Neoplasms; Neoplasms, | 1996 |
Mutagenic and epigenetic effects of DNA methylation.
Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; Enzymes; Gene Expression Regulation, Neoplasti | 1997 |
Altered DNA methylation and genome instability: a new pathway to cancer?
Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; DNA, Neoplasm; Genes, Tumor Suppressor; Humans | 1997 |
DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis.
Topics: 5-Methylcytosine; Alkylating Agents; Animals; Cytosine; DNA Damage; DNA Methylation; DNA Modificatio | 1997 |
Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis.
Topics: 5-Methylcytosine; Alleles; Animals; Cell Differentiation; Chromatin; CpG Islands; Cytosine; DNA Meth | 1997 |
Oncogenic mechanisms mediated by DNA methylation.
Topics: 5-Methylcytosine; Animals; Cytosine; DNA; DNA Methylation; Humans; Mammals; Mutation; Neoplasms; Nuc | 1997 |
Cytosine methylation and the ecology of intragenomic parasites.
Topics: Animals; Cytosine; DNA Methylation; DNA Transposable Elements; Gametogenesis; Gene Expression Regula | 1997 |
Mutagenesis in the P53 gene.
Topics: 5-Methylcytosine; Carcinogens, Environmental; Cytosine; DNA Damage; Genes, p53; Humans; Mutagens; Mu | 1997 |
Dynamic interrelationships between DNA replication, methylation, and repair.
Topics: 5-Methylcytosine; Animals; Chromatin; CpG Islands; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; C | 1997 |
Formation and repair of DNA lesions in the p53 gene: relation to cancer mutations?
Topics: 5-Methylcytosine; Animals; Benzo(a)pyrene; Breast Neoplasms; Carcinogens, Environmental; Colonic Neo | 1998 |
Cytosine methylation and human cancer.
Topics: Cell Transformation, Neoplastic; Cytosine; DNA Methylation; Humans; Neoplasms | 2000 |
DNA methylation: past, present and future directions.
Topics: 5-Methylcytosine; Antimetabolites, Antineoplastic; Azacitidine; Carcinogens; Chromatin; Cytosine; DN | 2000 |
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
Topics: 5-Methylcytosine; Acetylation; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Tr | 2001 |
Methylation matters.
Topics: 5-Methylcytosine; Chromosome Aberrations; CpG Islands; Cytosine; DNA Methylation; DNA Transposable E | 2001 |
Methylation, mutation and cancer.
Topics: 5-Methylcytosine; Animals; Cell Transformation, Neoplastic; Cytosine; Deamination; DNA; DNA, Neoplas | 1992 |
5-Methylcytosine as an endogenous mutagen in the p53 tumor suppressor gene.
Topics: 5-Methylcytosine; Animals; Cytosine; DNA; Genes, p53; Humans; Mutagens; Mutation; Neoplasms | 1991 |
Hypomethylation of DNA in the regulation of gene expression.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cell Differentiation; Cytosine; DNA; Gene Expression Regulat | 1988 |
7 trials available for cytosine and Neoplasms
Article | Year |
---|---|
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosine; Dioxolanes; Dose-R | 2009 |
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Cyt | 2006 |
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Topics: Antineoplastic Agents; Body Fluid Compartments; Cytosine; Dioxolanes; Dose-Response Relationship, Dr | 2006 |
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
Topics: Adult; Aged; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; D | 2008 |
[Bropirimine (U-54461S) phase I clinical studies].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cytosine; Drug Administration Schedule; Fe | 1996 |
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Dose-Response Relations | 2002 |
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Dioxol | 2002 |
89 other studies available for cytosine and Neoplasms
Article | Year |
---|---|
Photoreactive Cytosine-Functionalized Self-Assembled Micelles with Enhanced Cellular Uptake Capability for Efficient Cancer Chemotherapy.
Topics: Cytosine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Humans; Micelles; Neoplasms | 2021 |
Blood DNA methylation signatures are associated with social determinants of health among survivors of childhood cancer.
Topics: Cancer Survivors; Child; CpG Islands; Cytosine; DNA Methylation; Epigenesis, Genetic; Genome-Wide As | 2022 |
Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect.
Topics: Animals; CD8-Positive T-Lymphocytes; Cytosine; Guanine; Interferon-gamma; Killer Cells, Natural; Lym | 2022 |
Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A.
Topics: Animals; Cytosine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase | 2022 |
Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy.
Topics: Adjuvants, Immunologic; Cell Line, Tumor; Cytosine; Cytostatic Agents; Doxorubicin; Guanosine; Human | 2022 |
A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Topics: Animals; Antigens, Neoplasm; Cancer Vaccines; Cytosine; Guanine; Humans; Immune Checkpoint Inhibitor | 2022 |
The gene variant for desmin rs1058261 may protect against combined cancer and cardiovascular death, the Tampere adult population cardiovascular risk study.
Topics: Adult; Cardiovascular Diseases; Cytosine; Desmin; Genotype; Heart Disease Risk Factors; Humans; Neop | 2022 |
Determinants of DNMT2/TRDMT1 preference for substrates tRNA and DNA during the evolution.
Topics: Animals; Cytosine; DNA; DNA (Cytosine-5-)-Methyltransferases; Humans; Mammals; Methyltransferases; N | 2023 |
m
Topics: Animals; Cell Line, Tumor; Cytosine; DNA (Cytosine-5-)-Methyltransferases; DNA Breaks, Double-Strand | 2020 |
Methylation and demethylation of DNA and histones in chromatin: the most complicated epigenetic marker.
Topics: Animals; Chromatin; Cytosine; DNA Demethylation; DNA Methylation; Epigenesis, Genetic; Genetic Marke | 2017 |
TET1 deficiency attenuates the DNA damage response and promotes resistance to DNA damaging agents.
Topics: Cyclin B1; Cytosine; DNA Damage; DNA Methylation; DNA Repair; DNA-Activated Protein Kinase; Gene Exp | 2017 |
5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages.
Topics: 5-Methylcytosine; Adult; Aged; Animals; Cell-Free Nucleic Acids; Circulating Tumor DNA; Cytosine; DN | 2017 |
A bifunctional nanomodulator for boosting CpG-mediated cancer immunotherapy.
Topics: Cytosine; Doxorubicin; Guanine; Humans; Immunotherapy; Metal Nanoparticles; Nanoconjugates; Neoplasm | 2017 |
Global delay in nascent strand DNA methylation.
Topics: Cell Cycle; Cell Proliferation; CpG Islands; Cytosine; DNA; DNA (Cytosine-5-)-Methyltransferases; DN | 2018 |
A Tumor-Promoting Phorbol Ester Causes a Large Increase in APOBEC3A Expression and a Moderate Increase in APOBEC3B Expression in a Normal Human Keratinocyte Cell Line without Increasing Genomic Uracils.
Topics: Carcinogens; Cell Line; Cell Transformation, Neoplastic; Cytidine Deaminase; Cytosine; DNA, Single-S | 2019 |
Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
Topics: Catalytic Domain; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Cytidine Deaminase; Cytopl | 2019 |
Tight correlation of 5-hydroxymethylcytosine and Polycomb marks in health and disease.
Topics: 5-Methylcytosine; Cell Differentiation; Cell Line, Tumor; Cytosine; DNA Methylation; Epigenomics; Fe | 2013 |
PAPD5-mediated 3' adenylation and subsequent degradation of miR-21 is disrupted in proliferative disease.
Topics: Adenine; Base Sequence; Cytosine; Exoribonucleases; Gene Expression Profiling; Gene Expression Regul | 2014 |
Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A.
Topics: 5-Methylcytosine; Basic Helix-Loop-Helix Transcription Factors; Cell Cycle Proteins; Cell Line, Tumo | 2014 |
Decrease of 5-hydroxymethylcytosine in rat liver with subchronic exposure to genotoxic carcinogens riddelliine and aristolochic acid.
Topics: 5-Methylcytosine; Animals; Aristolochic Acids; Carcinogenesis; Carcinogens; Cytosine; DNA-Binding Pr | 2015 |
Uncovering the polymerase-induced cytotoxicity of an oxidized nucleotide.
Topics: Adenine; Base Pairing; Catalytic Domain; Crystallography, X-Ray; Cytosine; Cytotoxins; Deoxyguanine | 2015 |
Quantification of 5-methylcytosine, 5-hydroxymethylcytosine and 5-carboxylcytosine from the blood of cancer patients by an enzyme-based immunoassay.
Topics: 5-Methylcytosine; Cytosine; DNA; Epigenesis, Genetic; Humans; Immunoenzyme Techniques; Limit of Dete | 2014 |
CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer.
Topics: 5-Methylcytosine; Animals; Cell Death; Cell Line, Tumor; Cytidine; Cytidine Deaminase; Cytosine; Deo | 2015 |
Molecular biology: Salvaging the genome.
Topics: Animals; Cytidine; Cytidine Deaminase; Cytosine; Epigenesis, Genetic; Humans; Neoplasms | 2015 |
Intrinsic mutagenic properties of 5-chlorocytosine: A mechanistic connection between chronic inflammation and cancer.
Topics: Biomarkers, Tumor; Carcinogenesis; Chromatography, High Pressure Liquid; Cytosine; DNA Mutational An | 2015 |
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy.
Topics: 5-Methylcytosine; Alternative Splicing; Animals; Cell Line, Tumor; Cytosine; Epigenesis, Genetic; Ge | 2016 |
APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication.
Topics: Cytidine Deaminase; Cytosine; DNA Methylation; DNA Mutational Analysis; DNA Replication; Exome; Huma | 2016 |
3-methylcytosine in cancer: an underappreciated methyl lesion?
Topics: Biomarkers, Tumor; Cytosine; DNA Damage; DNA Methylation; DNA Repair; Humans; Neoplasms | 2016 |
Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.
Topics: Aged; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2016 |
Incorporation of 5-chlorocytosine into mammalian DNA results in heritable gene silencing and altered cytosine methylation patterns.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Cytosine; DNA; DNA Damage; DNA Replication; Gene Silenci | 2009 |
Label-free analysis of DNA methylation using optofluidic ring resonators.
Topics: Animals; Cell Proliferation; Cytosine; DNA Methylation; Epigenesis, Genetic; Equipment Design; Human | 2009 |
Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir.
Topics: Adenoviridae Infections; Adenoviruses, Human; Animals; Biological Transport; Cell Death; Cell Line; | 2010 |
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytos | 2011 |
Measuring topology of low-intensity DNA methylation sites for high-throughput assessment of epigenetic drug-induced effects in cancer cells.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Nucleus; Cytidine; Cytosine; DNA Methylat | 2010 |
Computational studies on effects of MDMA as an anticancer drug on DNA.
Topics: Adenine; Antineoplastic Agents; Base Pairing; Cytosine; DNA; Drug Design; Guanine; Humans; Intercala | 2010 |
Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cell Death; Cell Line, | 2010 |
Conservation and divergence of DNA methylation in eukaryotes: new insights from single base-resolution DNA methylomes.
Topics: Animals; CpG Islands; Cytosine; DNA Methylation; Embryonic Stem Cells; Epigenomics; Eukaryota; Evolu | 2011 |
Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization.
Topics: Algorithms; Base Composition; Cell Line, Tumor; Cytosine; DNA Copy Number Variations; Genomics; Guan | 2011 |
Structural basis for the inhibition of human alkyladenine DNA glycosylase (AAG) by 3,N4-ethenocytosine-containing DNA.
Topics: Catalytic Domain; Cytosine; DNA Damage; DNA Glycosylases; DNA, Neoplasm; Humans; Hydrogen Bonding; N | 2011 |
Quantum-chemical study of interactions of trans-resveratrol with guanine-thymine dinucleotide and DNA-nucleobases.
Topics: Adenine; Antineoplastic Agents, Phytogenic; Cytosine; DNA; DNA Breaks; Guanine; Humans; Hydrogen Bon | 2011 |
Effect of CpG methylation on DNA binding protein: molecular dynamics simulations of the homeodomain PITX2 bound to the methylated DNA.
Topics: Amino Acid Sequence; Binding Sites; CpG Islands; Cytosine; DNA; DNA Methylation; DNA-Binding Protein | 2011 |
Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®).
Topics: Adverse Drug Reaction Reporting Systems; Antiviral Agents; Cidofovir; Cytosine; Injections, Intrales | 2012 |
5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.
Topics: 5-Methylcytosine; Animals; Base Sequence; Brain; Brain Neoplasms; Carcinoma, Squamous Cell; Cell Lin | 2011 |
Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation.
Topics: 5-Methylcytosine; Cell Line, Tumor; Cell Transformation, Neoplastic; Colorectal Neoplasms; Cytosine; | 2012 |
Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.
Topics: 5-Methylcytosine; Animals; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cytosine; Dioxygenase | 2013 |
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Cytosine; Deoxycytidine; Gemcitabine; | 2012 |
Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors.
Topics: 5-Methylcytosine; 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Adenocarcinoma; Breast | 2002 |
Cellular vitamins, DNA methylation and cancer risk.
Topics: 5-Methylcytosine; Cytosine; DNA Methylation; Humans; Immunohistochemistry; Neoplasms; Risk Factors; | 2002 |
Troxacitabine (Shire Pharmaceuticals).
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cytosine; Dioxolanes; Humans; Neoplasms; S | 2002 |
A systematic profile of DNA methylation in human cancer cell lines.
Topics: 5-Methylcytosine; Azacitidine; Cluster Analysis; CpG Islands; Cytosine; Decitabine; DNA Methylation; | 2003 |
Troxacitabine: BCH 4556, SPD 758, Troxatyl.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytosine; Dioxolanes; Drug Industry; Humans; Infusi | 2003 |
Integrin beta3 Leu33Pro homozygosity and risk of cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Animals; Cytosine; Denmark; Disease Progression; Female; Ge | 2003 |
The formation of cytidine nucleotides and RNA cytosine from orotic acid by the Novikoff tumor in vitro.
Topics: Cytidine; Cytosine; In Vitro Techniques; Neoplasms; Nucleosides; Nucleotides; Orotic Acid; Pyrimidin | 1959 |
FRACTIONS WITH DIFFERING BASE COMPOSITION IN RNA FROM MALIGNANT CELLS OF MOUSE.
Topics: Adenine; Animals; Autoradiography; Base Composition; Cytosine; Electrophoresis; Guanine; Mice; Neopl | 1963 |
[EFFECT OF SOME PYRIMIDINE DERIVATIVES ON THE TOXIC AND ANTINEOPLASTIC ACTION OF SARCOLYSINE].
Topics: Antineoplastic Agents; Cytosine; Erythrocyte Count; Leukocyte Count; Melphalan; Neoplasm Metastasis; | 1963 |
[EFFECT OF SOME PYRIMIDINE DERIVATIVES ON THE GROWTH OF CROCKER'S SARCOMA].
Topics: Animals; Antineoplastic Agents; Cytosine; Mice; Neoplasms; Pharmacology; Pyrimidines; Research; Sarc | 1963 |
[ON THE EFFECT OF CERTAIN PYRIMIDINE DERIVATIVES ON THE METASTASIZATION OF TRANSPLANTABLE SSK RAT SARCOMA].
Topics: Cytosine; Neoplasm Metastasis; Neoplasms; Pharmacology; Pyrimidines; Rats; Research; Sarcoma; Sarcom | 1964 |
SYNERGISM OF THE ANTINEOPLASTIC ACTIVITY OF CYTOSINE ARABINOSIDE BY PORFIROMYCIN.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Body Weight; Cytarabine; Cytosine; Leukemia; | 1964 |
THE REVERSAL OF CYTOSINE ARABINOSIDE ACTIVITY IN VIVO BY DEOXYCYTIDINE.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cytarabine; Cytosine; Deoxycytidine; Leuke | 1964 |
THE EFFECT OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE HYDROCHLORIDE ON MURINE NEOPLASMS.
Topics: Animals; Anti-Bacterial Agents; Antibodies; Antineoplastic Agents; Blood Cells; Carcinoma, Ehrlich T | 1964 |
TUMOR AND VIRUS ANTIGENS OF SIMIAN VIRUS 40: DIFFERENTIAL INHIBITION OF SYNTHESIS BY CYTOSINE ARABINOSIDE.
Topics: Antigens; Antigens, Viral; Cytarabine; Cytosine; Humans; Idoxuridine; Metabolism; Neoplasms; Nucleos | 1965 |
SPECIFICITY OF DNA FROM NEOPLASTIC TISSUES IN VIVO AND IN VITRO.
Topics: Adenine; Animals; Carbon Isotopes; Cytosine; DNA; DNA, Neoplasm; Formates; Guanine; Histocytochemist | 1964 |
ON THE OXIDATIVE PHOSPHORYLATION AND NUCLEIC ACIDS METABOLISM IN SOME ORGANS OF ANIMALS WITH TRANSPLANTABLE TUMOURS.
Topics: Adenine; Carbohydrate Metabolism; Cytosine; DNA; DNA, Neoplasm; Glycolysis; Guanine; Intestines; Kid | 1964 |
COMPARATIVE STUDIES OF LEUKEMIC CELLS SENSITIVE AND RESISTANT TO CYTOSINE ARABINOSIDE.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Chromatography; Cytarabine; Cytosine; DNA; DNA, Neopl | 1965 |
BASE COMPOSITION OF HIGH MOLECULAR WEIGHT NUCLEAR RNA OF WALKER TUMOR AND LIVER OF THE RAT.
Topics: Adenine; Adenine Nucleotides; Animals; Base Composition; Carcinoma 256, Walker; Cytosine; Cytosine N | 1965 |
Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Cy | 2004 |
Determination of 5-methyl-cytosine and cytosine in tumor DNA of cancer patients.
Topics: 5-Methylcytosine; Cytosine; DNA Methylation; DNA, Neoplasm; Electrophoresis, Capillary; Humans; Neop | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; | 2005 |
Cidofovir and the black box warning.
Topics: Animals; Antineoplastic Agents; Cidofovir; Cytosine; Disease Progression; Drug Labeling; Humans; Lar | 2005 |
G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; Antineoplastic Agents; B-Lymphocytes; Carcinoma; Ce | 2006 |
DNA cytosine methylation profile in various cancer-related genes is altered in cultured rat hepatocyte cell lines as compared with primary hepatocytes.
Topics: Animals; Cell Culture Techniques; Cells, Cultured; CpG Islands; Cytosine; DNA Methylation; Genes, Ne | 2006 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; | 2007 |
The 5-methylcytosine content of DNA from human tumors.
Topics: 5-Methylcytosine; Brain Chemistry; Cytosine; DNA; DNA Restriction Enzymes; DNA, Neoplasm; Female; Hu | 1983 |
Extent of DNA methylation in human tumor cells.
Topics: 5-Methylcytosine; Base Composition; Cell Line; Chromatography, High Pressure Liquid; Cytosine; DNA; | 1983 |
Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants.
Topics: 5-Methylcytosine; Autoradiography; Cell Line; Cerebellar Neoplasms; Cytosine; DNA; Fibroblasts; Huma | 1983 |
A cytosine methyltransferase converts 5-methylcytosine in DNA to thymine.
Topics: 5-Methylcytosine; Cytosine; DNA; DNA-Cytosine Methylases; Escherichia coli; Humans; Methylation; Mol | 1995 |
Methylation and p16: suppressing the suppressor.
Topics: 5-Methylcytosine; Carrier Proteins; Cell Transformation, Neoplastic; Cocarcinogenesis; CpG Islands; | 1995 |
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.
Topics: 5-Methylcytosine; Alleles; Azacitidine; Base Sequence; Brain Neoplasms; Carcinoma, Non-Small-Cell Lu | 1995 |
Hypomethylation of DNA: a possible nongenotoxic mechanism underlying the role of cell proliferation in carcinogenesis.
Topics: 5-Methylcytosine; Animals; Cell Division; Cytosine; DNA; Female; Liver Neoplasms, Experimental; Male | 1993 |
Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots.
Topics: Acetoxyacetylaminofluorene; Aflatoxin B1; Binding Sites; Carcinogens; CpG Islands; Cytosine; DNA Met | 1998 |
DNA methylation influences the decatenation activity of topoisomerase II.
Topics: Animals; CpG Islands; Crithidia fasciculata; Cytosine; DNA Methylation; DNA Topoisomerases, Type II; | 2001 |
Chromosome-wide assessment of replication timing for human chromosomes 11q and 21q: disease-related genes in timing-switch regions.
Topics: Alzheimer Disease; Chromosome Mapping; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 21; Cyt | 2002 |
High-resolution liquid chromatographic analysis of methylated purine and pyrimidine bases in transfer RNA.
Topics: Adenine; Animals; Cattle; Chemical Phenomena; Chemistry; Chromatography, Liquid; Cytosine; Guanine; | 1976 |
Childhood cancer: the improving prognosis.
Topics: Asparaginase; Child; Cyclophosphamide; Cytosine; Daunorubicin; Doxorubicin; Drug Therapy, Combinatio | 1976 |
The cell cycle and cancer chemotherapy.
Topics: Antineoplastic Agents; Cell Cycle; Cyclophosphamide; Cytosine; DNA Replication; Dose-Response Relati | 1978 |
Phase I study of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP), an oral interferon inducer, in cancer patients.
Topics: Adult; Aged; Cytosine; Drug Evaluation; Humans; Interferon Inducers; Interferons; Male; Melanoma; Mi | 1986 |
Bropirimine.
Topics: Antineoplastic Agents; Cytosine; Drug Evaluation; Humans; Neoplasms | 1989 |
Patterns of DNA methylation and gene expression in human tumor cell lines.
Topics: Cell Line; Collagen; Cytosine; DNA, Neoplasm; Gene Expression Regulation; Humans; Methylation; Neopl | 1986 |
Flexibility of nucleic acid bases and its possible relationship with carcinogenesis.
Topics: Adenine; Animals; Cytosine; DNA; Guanine; Humans; Hydrogen Bonding; Neoplasms; Nucleic Acid Conforma | 1985 |